CureVac highlights shift to mRNA technology in seasonal influenza vaccine development: GlobalData
CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology
CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology
Public private partnership (PPP) with integrated strategy essential to achieve ‘TB Mukt Bharat’ by 2025
Sun Pharma is granted rights for marketing Sovateltide in India under the brand name Tyvalzi (Sovateltide)
The Leaders of G20 met in New Delhi and committed to strengthening global health and implementing one health approach
Marking a significant milestone in its commitment to holistic wellness
Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris
This is a strategic acquisition for Cipla South Africa to unlock the future growth opportunities in the South African market
The facility has a potential for capacity expansion up to 2 billion tablets/capsules per year
Subscribe To Our Newsletter & Stay Updated